Integrated Research Institute for Natural Ingredients and Functional Foods
Yangsan, 50612, South Korea
NCT Number: NCT03773315
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the Ulmus Macrocarpa Hance extract on lipid profile in adults with dyslipidemia for 12 weeks.
Looking for future studies?
Notify Me20 year–75 year
All sexes
Interventional
Not applicable
Yangsan, 50612, South Korea
Previous another our study have indicated that Ulmus Macrocarpa Hance extract (UMH) may have the ability to decrease blood cholesterol. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the UMH on lipid profile in adults with dyslipidemia; the safety of the compound are also evaluate. The Investigators examine total cholesterol, HDL-cholesterol, triglyceridemia, LDL-cholesterol, and other biochemical parameters at baseline, as well as after 6 and 12 weeks of intervention. Eighty adults were administered either 500 mg of UMH or a placebo each day for 12 weeks;
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Schisandra chinensis extract 500 mg/day for 12 weeks
Starch placebo 500 mg/day for 12 weeks
Time frame: 12 weeks
LDL cholesterol
Time frame: 12 weeks
Total cholesterol
Time frame: 12 weeks
Triglyceride
Time frame: 12 weeks
HDL cholesterol
Sang Yeoup Lee
Other
Effect of Ulmus Macrocarpa Hance Extract on Lipid Profile in Adults With Dyslipidemia: a RCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06380322
Cardiovascular Diseases, Diabetes Mellitus
Fort Carson, Colorado, United States
View Trial DetailsNCT05988866
Dyslipidemias, Hypercholesterolemia
Hamburg, Germany
View Trial DetailsNCT05075902
Cardiovascular Diseases, Chronic Disease
Uberlândia, Minas Gerais, Brazil
View Trial DetailsNCT07682285
Cancer-related Fatigue, Carcinoma
Taipei, Taiwan
View Trial Details